CTLA4 and neoplasm: ICIs enhance the recognition of T cells by tumor cells by targeting the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death receptor 1 (PD-1)/ligand 1 (PD-L1) to alter the immune escape microenvironment of tumors.